Jewish World Review

JWR's Pundits
World Editorial
Cartoon Showcase

Mallard Fillmore

Michael Barone
Mona Charen
Linda Chavez
Greg Crosby
Larry Elder
Don Feder
Suzanne Fields
James Glassman
Paul Greenberg
Bob Greene
Betsy Hart
Nat Hentoff
David Horowitz
Marianne Jennings
Michael Kelly
Mort Kondracke
Ch. Krauthammer
Lawrence Kudlow
Dr. Laura
John Leo
David Limbaugh
Michelle Malkin
Jackie Mason
Chris Matthews
Michael Medved
Kathleen Parker
Wes Pruden
Sam Schulman
Amity Shlaes
Roger Simon
Tony Snow
Thomas Sowell
Cal Thomas
Jonathan S. Tobin
Ben Wattenberg
George Will
Bruce Williams
Walter Williams
Mort Zuckerman

Consumer Reports

Skin patch reigns in overactive bladder | (UPI) -- A new skin patch, called Oxytrol(TM), can control an overactive bladder for up to four days, its developers say.

This twice-weekly patch controls incontinence without the side effects often associated with pills that produce the same result, they said. The Food and Drug Administration has approved the patch, made by Watson Pharmaceuticals, Inc., of Corona, Calif., as a treatment for the symptoms of urge urinary incontinence.

Affecting more than 33 million Americans, the condition is more common than diabetes and asthma.

"The approval of Oxytrol(TM) marks an important milestone for Watson," said Allen Chao, company chairman and chief executive officer.

Tests by more than 1,000 volunteers showed the patch can control symptoms over a three-to-four-day period without producing serious side effects.

"Side effects have long been a leading cause of treatment discontinuation among my patients suffering from overactive bladder," said Dr. Roger Dmochowski, professor of urology at Vanderbilt University and study investigator.

"Oxytrol's(TM) transdermal delivery system provides physicians and patients with a convenient new treatment option to help manage the symptoms of overactive bladder" with minimal side effects, he said.

Appreciate this type of reporting? Why not sign-up for the daily JWR update. It's free. Just click here.

Comment by clicking here.


© 2003, UPI